GoKawiilHuidaGene's gene-editing DMD therapy showed limited benefit, Cell study confirms
A Cell publication details results from HuidaGene's first-in-human trial of a CRISPR base-editing gene therapy for Duchenne muscular dystrophy, confirming that one boy died after receiving a high dose. The study found the treatment edited some target genes in the four participants but produced only limited therapeutic effect, while the boy who died suffered a severe immune reaction beginning with abdominal pain and fever within 24 hours of dosing.
GoKawiil's interpretation of the reporting above, not reported fact.
The published data give researchers their first detailed look at what went wrong, which could inform dosage limits for future AAV-delivered gene-editing trials. The months-long gap between the death and public disclosure has already drawn criticism of HuidaGene and renewed scrutiny of China's accelerated clinical-trial pathways, suggesting regulators and companies may face pressure to tighten safety-reporting timelines.
- A Cell paper confirms a boy died after high-dose treatment in HuidaGene's DMD gene-editing trial.
- The therapy edited some target genes but delivered only limited therapeutic benefit across four participants.
- The case has intensified scrutiny of delayed safety disclosures and China's fast-track trial system.
Source: nature.com, 2026-10-27
Published there as: “Gene therapy that led to boy’s death had limited efficacy”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.